- CureMetrix, an innovator in AI-driven mammography solutions, has partnered with SimonMed Imaging, a prominent provider of outpatient medical imaging services in the United States.

- The strategic collaboration will bring CureMetrix's cutting-edge AI technology, cmAngio, to SimonMed Imaging's extensive network of facilities across the nation.

cmAngio: Enhancing Breast Cancer Detection with AI

cmAngio is an FDA-cleared AI-powered software designed to analyze mammograms and detect potential indicators of breast cancer, including Breast Arterial Calcifications (BAC). The software seamlessly integrates with existing mammography systems, providing radiologists with an additional layer of analysis to aid in the early detection and diagnosis of breast cancer.

Key Features and benefits of cmAngio include: